Antibiotic Use Does Not Appear to Influence Response to Nivolumab. - Université de Bourgogne Accéder directement au contenu
Article Dans Une Revue Anticancer Research Année : 2017

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Résumé

Background: Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC). Patients and Methods: Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab between 2015 and 2016 (3 mg/kg i.v. q2w). The association between RECIST response and antibiotic usage was determined using Chi-square and Cox proportional hazard model. Results: A total of 17, 21 and 36 patients experienced response, stable disease and progression disease under nivolumab. Only 15 (20.3%) patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment. We found a similar response rate for the two populations, without impact of antibiotic exposure (Chi-square test p= 0.75). Moreover, we observed no impact of antibiotic medication on progression-free survival under nivolumab (log-rank test, p= 0.72). Conclusion: Microbiota modification induced by antibiotics does not appear to affect the efficacy of nivolumab in patients with NSCLC.

Domaines

Cancer

Dates et versions

hal-01545832 , version 1 (23-06-2017)

Identifiants

Citer

Coureche Kaderbhai, Corentin Richard, Jean David Fumet, Anne Aarnink, Pascal Foucher, et al.. Antibiotic Use Does Not Appear to Influence Response to Nivolumab.. Anticancer Research, 2017, 37 (6), pp.3195-3200. ⟨10.21873/anticanres.11680⟩. ⟨hal-01545832⟩
58 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More